ArticleInvestigational new drugs2023

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.

Antonio Jimeno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.